Biogen (BIIB) Spikes 14% After FDA Posts Briefing Documents for Alzheimer's Drug Aducanumab

(Updated - November 4, 2020 10:15 AM EST)

Biogen (NASDAQ: BIIB) shares spiked 14% and were halted due to volatility after FDA briefing documents for a review of Alzheimer's drug Aducanumab were posted.

Aducanumab was found to be effective enough to support approval, the FDA panel said in the documents.

You May Also Be Interested In

• FDA: classifies Insulet OmniPod pods recall as Class I due to serious injury risk
• Newron meets with FDA over US trial enrollment hold
• NewcelX gets FDA feedback supporting NCEL-101 diabetes trial path